Sunshine Biopharma Inc. (SBFM): Entry into a Material Definitive Agreement
Sunshine Biopharma Inc. (SBFM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 sunshine_ex1001.htm RELEASE AGREEMENT Exhibit 10.1 AGREEMENT OF TRANSACTION AND MUTUAL RELEASE Between: Malek Chamoun , domiciled at XXXXXXXXXX (hereinafter “ Chamoun ”) And: Sunshine Biopharma inc ., having a place of business at 1565 Lionel-Boulet boulevard, Varennes,
How this was made
The 30-second read
Why it matters
Sunshine and Nora agree to fully settle and release claims in exchange for a CAD 1.5M payment, with portions paid by Sunshine (earn-out) and Nora (bonuses and indemnity). The release also terminates non-competition and non-solicitation obligations for Chamoun while preserving confidentiality obligations.
Market read
Traders get a concrete, newly filed disclosure of a cash settlement amount and payment timing tied to share-sale evidence, plus termination of non-compete/non-solicit obligations.
What to watch
The agreement requires Chamoun to sell all common shares within 30 days and conditions payment timing on evidence of sale, which could create a short-term overhang if the shares are liquid and the market interprets it as insider selling.
Background
The 8-K describes a dispute initiated by Chamoun (former Nora CEO) alleging amounts owed under a 2022 share purchase agreement and employment termination-related damages; the parties mediated on July 8, 2026.
Ticker impact
Sunshine Biopharma entered a material definitive agreement to settle disputes with Chamoun, including a CAD 1.5M payment allocated across earn-out and bonuses.
Likely limited near-term impact unless the company’s disclosures indicate the payment is material versus cash/earnings; otherwise it is a one-off legal settlement.
The filing provides the settlement amount and payment allocation but does not include guidance, financial statements, or explicit balance-sheet impact. Traders may still adjust risk around contingent liabilities and cash usage.
Market effects
Limited sector read-across; this appears company-specific litigation settlement rather than a regulatory or industry-wide development.
No clear regional market linkage beyond Canadian corporate/legal context.
Low global relevance; no cross-border deal, product, or regulatory action disclosed.
Counterpoint
If the CAD 1.5M settlement is larger than expected relative to Sunshine’s liquidity, the market could reprice downside risk even without guidance changes.
Key entities
- issuerSunshine Biopharma Inc.
Subject of the 8-K, party to the settlement agreement and payer of part of the CAD 1.5M amount.
- counterpartyMalek Chamoun
Former Nora CEO who filed an originating application and cross-claims; receives the settlement payment and releases are exchanged.
- issuer_relatedNora Pharma inc.
Another corporation in the settlement, responsible for paying specified bonus and indemnity components.
